## SAFETY DATA SHEET



Label No :50630

AQUAPRIMER 2900-06 - All variants

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name : AQUAPRIMER 2900-06 - All variants

1.2 Relevant identified uses of the substance or mixture and uses advised against

Product use : Paint.

1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person : Pro

responsible for this SDS

: Prod-safe@teknos.com

**National contact** 

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

1.4 Emergency telephone number

**National advisory body/Poison Centre** 

Telephone number : National Poisons Information Centre: 01 809 2566

### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

**Product definition**: Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Skin Sens. 1, H317

Aquatic Chronic 3, H412

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

#### 2.2 Label elements

Hazard pictograms



Signal word : Warning

**Hazard statements**: H317 - May cause an allergic skin reaction.

H412 - Harmful to aquatic life with long lasting effects.

**Precautionary statements** 

**Prevention**: P280 - Wear protective gloves.

P273 - Avoid release to the environment.

P261 - Avoid breathing vapour.

**Response**: P362 + P364 - Take off contaminated clothing and wash it before reuse.

P302 + P352 - IF ON SKIN: Wash with plenty of water.

Storage : Not applicable.

Disposal : P501 - Dispose of contents and container in accordance with all local, regional,

national and international regulations.

Date of issue/Date of revision: 28/09/2023Date of previous issue: 13/06/2022Version: 1.071/16

### **SECTION 2: Hazards identification**

**Hazardous ingredients** 

: Contains: 1,2-benzisothiazol-3(2H)-one; 2-methyl-2H-isothiazol-3-one and 2-Octyl-2H-isothiazol-3-one

Supplemental label elements

: Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist. Contains biocidal products for in-can preservation: BIT and Bronopol and MIT and OIT.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles .

#### 2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII : This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

Other hazards which do not result in classification

: None known.

### **SECTION 3: Composition/information on ingredients**

3.2 Mixtures : Mixture

Product/ingredient name	Identifiers	%	Classification	Specific Conc. Limits, M-factors and ATEs	Type
Manium dioxide	REACH #: 01-2119489379-17 EC: 236-675-5 CAS: 13463-67-7	≥10 - ≤25	Carc. 2, H351 (inhalation)	-	[1] [*]
2-Butoxyethanol	REACH #: 01-2119475108-36 EC: 203-905-0 CAS: 111-76-2 Index: 603-014-00-0	<1	Acute Tox. 4, H302 Acute Tox. 3, H331 Skin Irrit. 2, H315 Eye Irrit. 2, H319	ATE [Oral] = 1200 mg/kg ATE [Inhalation (vapours)] = 3 mg/l	[1] [2]
1,2-benzisothiazol-3(2H)- one	EC: 220-120-9 CAS: 2634-33-5 Index: 613-088-00-6	<0.05	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1, H317 Aquatic Acute 1, H400	ATE [Oral] = 1020 mg/kg Skin Sens. 1, H317: C ≥ 0.05% M [Acute] = 1	[1]
Bronopol	EC: 200-143-0 CAS: 52-51-7 Index: 603-085-00-8	≤0.1	Acute Tox. 4, H302 Acute Tox. 4, H312 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT SE 3, H335 Aquatic Acute 1, H400	ATE [Oral] = 307 mg/kg ATE [Dermal] = 1100 mg/kg M [Acute] = 10	[1]
2-methyl-2H-isothiazol- 3-one	EC: 220-239-6 CAS: 2682-20-4	<0.01	Acute Tox. 3, H301 Acute Tox. 3, H311 Acute Tox. 2, H330 Skin Corr. 1B, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 EUH071	ATE [Oral] = 100 mg/kg ATE [Dermal] = 300 mg/kg ATE [Inhalation (dusts and mists)] = 0.11 mg/l Skin Sens. 1, H317: C ≥ 0.0015% M [Acute] = 10 M [Chronic] = 1	[1]
2-Octyl-2H-isothiazol-3-one	EC: 247-761-7	<0.025	Acute Tox. 3, H301	ATE [Oral] = 125	[1]

Date of issue/Date of revision : 28/09/2023 Date of previous issue : 13/06/2022 Version : 1.07 2/16

Label No :50630

SECTION 3: Composition/information on ingredients								
CAS: 26530-20-1 Index: 613-112-00-5	Skin Corr. 1, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 EUH071 See Section 16 for the full text of the H statements declared  311 mg/kg ATE [Inhalation (dusts and mists)] = 0.27 mg/l Skin Sens. 1, H317: C ≥ 0.0015% M [Acute] = 100 M [Chronic] = 100							
	above.							

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

#### **Type**

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [\*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter ≤ 10 µm not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

Eye contact

: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs.

Inhalation

Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

**Skin contact** 

: Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.

Ingestion

: Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

**Protection of first-aiders** 

: No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

### 4.2 Most important symptoms and effects, both acute and delayed

**Over-exposure signs/symptoms** 

**Eye contact** : No specific data. **Inhalation** : No specific data.

Date of issue/Date of revision : 28/09/2023 Date of previous issue : 13/06/2022 Version : 1.07 3/16

AQUAPRIMER 2900-06 - All variants

**Label No :**50630

### **SECTION 4: First aid measures**

Skin contact

: Adverse symptoms may include the following:

irritation redness

Ingestion : No specific data.

### 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician

: Treat symptomatically. Contact poison treatment specialist immediately if large

quantities have been ingested or inhaled.

**Specific treatments** : No specific treatment.

### **SECTION 5: Firefighting measures**

### 5.1 Extinguishing media

Suitable extinguishing media

: Use an extinguishing agent suitable for the surrounding fire.

**Unsuitable extinguishing** media

: None known.

#### 5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture : In a fire or if heated, a pressure increase will occur and the container may burst. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.

**Hazardous combustion** products

: Decomposition products may include the following materials:

metal oxide/oxides

#### 5.3 Advice for firefighters

**Special protective actions** for fire-fighters

: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

**Special protective** equipment for fire-fighters Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

For emergency responders: If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

6.2 Environmental precautions

: Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.

### 6.3 Methods and material for containment and cleaning up

**Small spill** 

: Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Version : 1.07 4/16 Date of issue/Date of revision : 28/09/2023 · 13/06/2022 Date of previous issue Label No :50630

### **SECTION 6: Accidental release measures**

#### Large spill

: Stop leak if without risk. Move containers from spill area. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product.

# 6.4 Reference to other sections

: See Section 1 for emergency contact information.

See Section 8 for information on appropriate personal protective equipment.

See Section 13 for additional waste treatment information.

### **SECTION 7: Handling and storage**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 7.1 Precautions for safe handling

### **Protective measures**

: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapour or mist. Avoid release to the environment. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.

# Advice on general occupational hygiene

Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.

#### 7.3 Specific end use(s)

Recommendations : Not available.

Industrial sector specific : Not available.

solutions

### SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

### 8.1 Control parameters

### Occupational exposure limits

Product/ingredient name	Exposure limit values
	NAOSH (Ireland, 5/2021). Absorbed through skin. Notes: EU derived Occupational Exposure Limit Values  OELV-8hr: 20 ppm 8 hours.  OELV-8hr: 98 mg/m³ 8 hours.  OELV-15min: 50 ppm 15 minutes.  OELV-15min: 246 mg/m³ 15 minutes.

### **Biological exposure indices**

 Date of issue/Date of revision
 : 28/09/2023
 Date of previous issue
 : 13/06/2022
 Version
 : 1.07
 5/16

 AQUAPRIMER 2900-06 - All variants
 Label No
 : ₹0630

### **SECTION 8: Exposure controls/personal protection**

Product/ingredient name	Exposure indices
	NAOSH (Ireland, 1/2011) BMGV: 200 mg/g creatinine, BAA [in urine]. Sampling time: end of shift - As soon as possible after exposure ceases.

### Recommended monitoring procedures

: Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

### **DNELs/DMELs**

DNEL   Long term Oral   Short term Oral   Short term Oral   DNEL   Long term   Short term Oral   Short term	Product/ingredient name	Type	Exposure	Value	Population	Effects
DNEL DNEL Long term inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL DNEL Dnet term Inhalation DNEL Dnet Dnet Inhalation DNEL Dnet Dnet Dnet Dnet Dnet Dnet Dnet Dnet	<b>2</b> -Butoxyethanol	DNEL	Long term Oral			Systemic
DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Dermal DNEL Short term DNEL Short term DNEL Long term DNEL Long term DNEL Long term DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL		DNEL	Short term Oral			Svstemic
Inhalation   Long term   Inhalation   DNEL   Short term   Inhalation   DNEL   Short term   Inhalation   DNEL   Short term   Inhalation   DNEL   Short term   Inhalation   DNEL   Long term Dermal   Inhalation   DNEL   Long term Dermal   Inhalation   DNEL   Long term Dermal   DNEL   Short term Oral   DNEL   Short term Dermal   DNEL   Long term Dermal   DNEL   Long term Dermal   DNEL   DNEL   Short term Dermal   DNEL   D						,
DNEL Short term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Dermal DNED		DNEL		59 mg/m³		Systemic
Inhalation   Short term   Inhalation   Inh				, ,		
DNEL Short term Inhalation DNEL Long term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL DNE		DNEL		98 mg/m³	Workers	Systemic
Inhalation Short term Inhalation DNEL Short term Inhalation DNEL Long term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Dong term Dermal DNEL Long term Dermal DNEL Dong term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL DNE		DNFI		147 mg/m³	General	Local
DNEL Short term Inhalation DNEL DNEL Long term Dermal DNEL Long term Dermal Inhalation DNEL DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL		DIVLE		l + / mg/m		Local
DNEL   Short term   Inhalation   DNEL   Short term   Inhalation   DNEL   Short term   Inhalation   DNEL   Long term Dermal   Long term Dermal   Long term Dermal   DNEL   DNEL   Short term Dermal   Long term Dermal   DNEL   DNEL   Short term Dermal   Long term Dermal   DNEL   Short term Dermal   DNEL   Short term Dermal   Long term Dermal   DNEL   DNEL   Short term Dermal   DNEL   DNE		DNEL		246 mg/m <sup>3</sup>		Local
Inhalation Short term Inhalation DNEL Long term Dermal DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL						
DNEL   Short term   1091 mg/ m³   Workers   Systemic   Morkers   Systemic   S		DNEL		426 mg/m <sup>3</sup>		Systemic
Inhalation   DNEL   Long term Dermal   Long term Dermal   Long term Dermal   DNEL   Long term Dermal   Long term   Long term Dermal   Long term D		חארו		1001		Customia
DNEL   Long term Dermal   DNEL   Long term Dermal   DNEL   Long term Dermal   DNEL   Long term   DNEL   DNE		DNEL			vvorkers	Systemic
DNEL Long term Dermal 0.966 mg/ kg bw/day 1.2 mg/m³ lnhalation DNEL Long term lnhalation DNEL Long term Dermal 1 halation DNEL Long term Dermal 1 halation DNEL Long term Dermal 1 halation DNEL Long term Dermal DNEL Long term Oral DNEL Short term Oral DNEL Short term Oral DNEL Short term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Dnemal DNEL Dnemal	1 2-benzisothiazol-3(2H)-one	DNFI			General	Systemic
DNEL Long term Dermal Ngbw/day 1.2 mg/m³ General population DNEL Long term Dermal Inhalation DNEL Short term Dermal DNEL Long term Oral DNEL Short term Oral DNEL Short term Oral DNEL Short term Oral DNEL Cong term One Inhalation DNEL Cong term Oral DNEL Cong term One Inhalation DNEL Short term Oral DNEL Short term Oral DNEL Cong term Oral DNEL Cong term Oral DNEL Cong term One Inhalation DNEL	1,2 55112.5511114251 5(21.1) 5115	5.122	Long tom Domai			Cyclonic
DNEL DNEL Dong term Inhalation Long term Dermal DNEL Short term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL		DNEL	Long term Dermal			Systemic
DNEL						
Bronopol  DNEL Long term Inhalation DNEL Short term Dermal DNEL Long term Oral DNEL Short term Oral DNEL Long term Oral DNEL Short term Oral		DNEL		1.2 mg/m <sup>3</sup>		Systemic
Inhalation   Short term Dermal   A μg/cm²   General population   General population   Cocal population   General population   Cocal		DNIEL		6 01 mg/m³		Cuatamia
Bronopol  DNEL DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL		DINEL		0.61 mg/m	vvoikeis	Systemic
DNEL DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Oral DNEL Long term Oral DNEL Short term Oral DNEL Short term Oral DNEL Short term Oral DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term O.6 mg/m³ General population DNEL Long term Dermal DNEL Short term O.6 mg/m³ General population DNEL Short term O.6 mg/m³ General population DNEL Short term O.7 mg/kg bw/day DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Dermal Short term Dermal DNEL Short term Dermal Short term Dermal DNEL Short term Dermal Short term Dermal DNEL Short term Dermal DNEL Short term Dermal Short term Short term Dermal Short term Short term Short term Short term Short term Dermal Short term Short ter	Bronopol	DNEL		4 ua/cm²	General	Local
DNEL Short term Dermal DNEL Short term Oral DNEL Long term Dermal DNEL Short term Oral DNEL Short term Oral DNEL Long term Dermal DNEL Short term One DNEL Sho	'			1 3		
DNEL DNEL Long term Dermal DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Short term Oral DNEL Short term Oral DNEL Long term Dermal Inhalation DNEL Short term Dermal Systemic Systemic DNEL Short term Dermal Systemic Systemic Systemic DNEL Short term Dermal Systemic Systemic Systemic DNEL Short term Dermal Systemic Systemic Systemic DNEL Short term Dermal Systemic Systemic Systemic Systemic Systemic Systemic DNEL Short term Dermal Systemic Systemi		DNEL	Long term Dermal	4 µg/cm²		Local
DNEL Long term Dermal Long term Oral DNEL Short term Oral DNEL Long term Dermal Inhalation DNEL Short term Dermal Inhalation DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Inhalation DNEL Short term Dermal DNEL Short term Inhalation DNEL Short term Dermal Systemic Dopulation DNEL Short term Dermal Systemic Dopulation DNEL Short term Dermal DNEL Short term DNEL Short				_ , _		
DNEL Long term Oral 0.18 mg/ kg bw/day population DNEL Short term Oral 0.5 mg/kg bw/day population DNEL Short term 0.6 mg/m³ General population DNEL Long term 1.0 mg/m³ General population DNEL Long term 1.0 mg/m³ General population DNEL Long term Dermal 0.7 mg/kg bw/day population DNEL Short term 1.8 mg/m³ General population DNEL Short term 1.8 mg/m³ General population DNEL Long term Dermal 2 mg/kg bw/day DNEL Short term Dermal 2.1 mg/kg bw/day DNEL Short term Dermal 2.1 mg/kg bw/day population DNEL Short term Dermal 2.1 mg/kg bw/day population DNEL Short term Dermal 2.1 mg/kg bw/day population						
DNEL Short term Oral						
DNEL Short term Oral		DINLL	Long term Oral			Oysternic
DNEL Short term Inhalation DNEL Long term Dermal DNEL Short term Inhalation DNEL Short term Dermal DNEL Short term Inhalation DNEL Short term Dermal DNEL Short term Dermal DNEL Short term DN		DNEL	Short term Oral			Systemic
Inhalation Long term Inhalation DNEL Long term Dermal DNEL Short term Inhalation DNEL Short term DNEL Short term Inhalation DNEL Short term DNEL DNEL Short term DNEL Short te				,		-
DNEL Long term Inhalation DNEL Long term Dermal DNEL Short term Dermal DNEL Long term Dermal Inhalation DNEL Short term Dermal Long term Dermal DNEL Short term Dermal Systemic population DNEL Short term Dermal Systemic population DNEL Short term Dermal 2 mg/kg bw/day DNEL Short term Dermal Systemic Systemic population DNEL Short term Dermal Systemic Systemic Systemic population DNEL Short term Dermal Dermal Systemic population DNEL Short term Dermal Dermal Systemic population		DNEL		0.6 mg/m <sup>3</sup>		Local
Inhalation Long term Dermal  DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Dermal DNEL DNEL Short term Dermal DNEL DNEL Short term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL		חארו		0.6 3		Customia
DNEL Short term Dermal DNEL Short term DN		DINEL		0.6 mg/m²		Systemic
DNEL Short term Dermal DNEL Short term DNEL Sh		DNEL		0.7 ma/ka		Svstemic
DNEL Short term Inhalation Long term Dermal DNEL Short term DNEL Shor						
DNEL Long term Dermal 2 mg/kg bw/day  DNEL Short term Dermal 2 mg/kg bw/day  DNEL Short term Dermal 2.1 mg/kg General population  Systemic Systemic population		DNEL			General	Systemic
DNEL Short term Dermal bw/day Systemic bw/day Systemic bw/day population		5				
DNEL Short term Dermal 2.1 mg/kg General Systemic bw/day population		DNEL	Long term Dermal		Workers	Systemic
bw/day population		DNEL	Short term Dermal		General	Systemic
DNEL Short term 2.5 mg/m³ Workers Local				bw/day		-
		DNEL	Short term	2.5 mg/m <sup>3</sup>	Workers	Local

Date of issue/Date of revision : 28/09/2023 Date of previous issue : 13/06/2022 Version : 1.07 6/16 Label No :50630

### SECTION 8: Exposure controls/personal protection

		Inhalation			
	DNEL	Long term	2.5 mg/m <sup>3</sup>	Workers	Local
		Inhalation			
	DNEL	Long term	3.5 mg/m³	Workers	Systemic
		Inhalation	- "		
	DNEL	Short term Dermal	6 mg/kg bw/day	Workers	Systemic
	DNEL	Short term	10.5 mg/m <sup>3</sup>	Workers	Systemic
		Inhalation			
2-methyl-2H-isothiazol-3-one	DNEL	Long term	0.021 mg/	General	Local
		Inhalation	m³	population	
	DNEL	Long term	0.021 mg/	Workers	Local
	DATE	Inhalation	m³	0 1	0
	DNEL	Long term Oral	0.027 mg/	General	Systemic
	DNEI	Chart tarms	kg bw/day	population	Lasal
	DNEL	Short term Inhalation	0.043 mg/ m³	General	Local
	DNEL	Short term	0.043 mg/	population Workers	Local
	DINEL	Inhalation	m <sup>3</sup>	AA OI VCI 2	LUCAI
	DNEL	Short term Oral	0.053 mg/	General	Systemic
	DINEL	Short term Oral	kg bw/day	population	- Cystellile

#### **PNECs**

No PNECs available

#### 8.2 Exposure controls

Appropriate engineering controls

: Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

#### **Individual protection measures**

**Hygiene measures** 

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

### **Eye/face protection**

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

### **Skin protection**

**Hand protection** 

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

Recommendations: Wear suitable gloves tested to EN374.

> 8 hours (breakthrough time): Nitrile gloves. thickness > 0.3 mm Not recommended polyvinyl alcohol (PVA) gloves

**Body protection** 

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Date of issue/Date of revision : 28/09/2023 · 13/06/2022 Version : 1.07 7/16 Date of previous issue Label No :50630

### SECTION 8: Exposure controls/personal protection

**Respiratory protection** 

: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Filter type (spray application): A P

**Environmental exposure** controls

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

### **SECTION 9: Physical and chemical properties**

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

### 9.1 Information on basic physical and chemical properties

**Appearance** 

Physical state : Liquid.

Colour : Various

Odour : Slight

Odour threshold : Not available.

Melting point/freezing point

Initial boiling point and

boiling range

: Not available.

Ingredient name	°C	°F	Method
water	100	212	

Flammability : Not available.

Lower and upper explosion

limit

: Lower: Not applicable. Upper: Not applicable.

Flash point : Closed cup: >100°C (>212°F)

Auto-ignition temperature : Not available.

Decomposition temperature : Not available.

**PH** : 8 to 8.5 [Conc. (% w/w): 100%]

Viscosity : Not available.

Solubility(ies)

Not available.

Solubility in water : Not available.

Partition coefficient: n-octanol/ : Not applicable.

water

Vapour pressure :

	Vapour Pressure at 20°C			Vapour Pressure at 20°C Vapour pressure at			re at 50°C
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method	
water	17.5	2.3					

Relative density : Not available.

Density : 1.2 g/cm³

Vapour density : Not available.

Explosive properties : Not available.

Oxidising properties : Not available.

**Particle characteristics** 

Median particle size : Not applicable.

Date of issue/Date of revision: 28/09/2023Date of previous issue: 13/06/2022Version: 1.078/16

Label No :50630

### **SECTION 10: Stability and reactivity**

10.1 Reactivity

: No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability

: The product is stable.

10.3 Possibility of hazardous reactions

: Under normal conditions of storage and use, hazardous reactions will not occur.

**10.4 Conditions to avoid** 

: No specific data.

10.5 Incompatible materials

: No specific data.

10.6 Hazardous decomposition products

•

: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

### **SECTION 11: Toxicological information**

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

### **Acute toxicity**

Product/ingredient name	Result	Species	Dose	Exposure
7,2-benzisothiazol-3(2H)- one	LD50 Oral	Rat	1020 mg/kg	-
Bronopol	LC50 Inhalation Dusts and mists	Rat	>0.588 mg/l	4 hours
	LD50 Dermal	Rat	4750 mg/kg	-
	LD50 Oral	Rat	307 mg/kg	-
2-methyl-2H-isothiazol- 3-one	LC50 Inhalation Dusts and mists	Rat	0.11 mg/l	4 hours
2-Octyl-2H-isothiazol-3-one	LD50 Dermal	Rabbit	690 mg/kg	-
•	LD50 Oral	Rat	550 mg/kg	-

Conclusion/Summary

: Based on available data, the classification criteria are not met.

### **Acute toxicity estimates**

Route	ATE value
Mhalation (vapours)	380.1 mg/l

### **Irritation/Corrosion**

Product/ingredient name	Result	Species	Score	Exposure	Observation
Manium dioxide	Skin - Mild irritant	Human	-	72 hours 300	-
				ug I	
2-Butoxyethanol	Eyes - Moderate irritant	Rabbit	-	24 hours 100	-
				mg	
	Eyes - Severe irritant	Rabbit	-	100 mg	-
	Skin - Mild irritant	Rabbit	-	500 mg	-
1,2-benzisothiazol-3(2H)-one	Skin - Mild irritant	Human	-	48 hours 5 %	-
Bronopol	Skin - Mild irritant	Rabbit	-	24 hours 500	-
				mg	
	Skin - Moderate irritant	Human	-	10 mg	-
	Skin - Moderate irritant	Rabbit	-	80 mg	-
2-Octyl-2H-isothiazol-3-one	Eyes - Severe irritant	Rabbit	-	100 mg	-

Conclusion/Summary

: Based on available data, the classification criteria are not met.

Skin Eyes : Based on available data, the classification criteria are not met.: Based on available data, the classification criteria are not met.

Respiratory

: Based on available data, the classification criteria are not met.

**Sensitisation** 

Conclusion/Summary

: May cause an allergic skin reaction.

Skin

: May produce an allergic reaction.

Respiratory

: Based on available data, the classification criteria are not met.

: 13/06/2022

Date of issue/Date of revision

AQUAPRIMER 2900-06 - All variants

Version : 1.07 9/16

**Label No :** 50630

### **SECTION 11: Toxicological information**

#### **Mutagenicity**

**Conclusion/Summary**: Based on available data, the classification criteria are not met.

### **Carcinogenicity**

It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantities leading to significant impairment of particle clearance mechanisms in the lung.

**Conclusion/Summary**: Based on available data, the classification criteria are not met.

**Reproductive toxicity** 

**Conclusion/Summary**: Based on available data, the classification criteria are not met.

**Teratogenicity** 

**Conclusion/Summary**: Based on available data, the classification criteria are not met.

### Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
<b>B</b> ronopol	Category 3	-	Respiratory tract irritation

### Specific target organ toxicity (repeated exposure)

Not available.

#### **Aspiration hazard**

Not available.

Information on likely routes

of exposure

: Not available.

### Potential acute health effects

Eye contactInhalationNo known significant effects or critical hazards.No known significant effects or critical hazards.

**Skin contact**: May cause an allergic skin reaction.

**Ingestion** : No known significant effects or critical hazards.

### Symptoms related to the physical, chemical and toxicological characteristics

Eye contact : No specific data.

Inhalation : No specific data.

**Skin contact**: Adverse symptoms may include the following:

irritation redness

Ingestion : No specific data.

#### Delayed and immediate effects as well as chronic effects from short and long-term exposure

**Short term exposure** 

Potential immediate : Not available.

effects

Potential delayed effects : Not available.

**Long term exposure** 

Potential immediate : Not available.

effects

Potential delayed effects : Not available.

Potential chronic health effects

Not available.

**Conclusion/Summary**: Based on available data, the classification criteria are not met.

General : Once sensitized, a severe allergic reaction may occur when subsequently exposed

to very low levels.

**Carcinogenicity** : No known significant effects or critical hazards.

Date of issue/Date of revision : 28/09/2023 Date of previous issue : 13/06/2022 Version : 1.07 10/16

Label No : 50630

### **SECTION 11: Toxicological information**

: No known significant effects or critical hazards. Mutagenicity

**Reproductive toxicity** : No known significant effects or critical hazards.

### 11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

Not available.

11.2.2 Other information

Not available.

### **SECTION 12: Ecological information**

### 12.1 Toxicity

Product/ingredient name	Result	Species	Exposure
itanium dioxide	Acute LC50 3 mg/l Fresh water	Crustaceans - Ceriodaphnia dubia - Neonate	48 hours
	Acute LC50 6.5 mg/l Fresh water	Daphnia - <i>Daphnia pulex</i> - Neonate	48 hours
	Acute LC50 >1000000 μg/l Marine water	Fish - Fundulus heteroclitus	96 hours
2-Butoxyethanol	Acute EC50 >1000 mg/l Fresh water	Daphnia - <i>Daphnia magna</i>	48 hours
	Acute LC50 800000 µg/l Marine water	Crustaceans - Crangon crangon	48 hours
	Acute LC50 1250000 µg/l Marine water	Fish - Menidia beryllina	96 hours
1,2-benzisothiazol-3(2H)-one	Acute EC50 0.36 mg/l Marine water	Algae - Skeletonema Costatum	72 hours
, ,	Acute EC50 3.7 mg/l	Daphnia - Daphnia Magna	48 hours
	Acute LC50 1.9 mg/l Fresh water	Fish - Onorhynchus Mykiss	96 hours
	Acute NOEC 0.15 mg/l Marine water	Algae - Skeletonema Costatum	72 hours
Bronopol	Acute EC50 0.4 mg/l	Algae	72 hours
	Acute EC50 0.02 ppm Fresh water	Algae - Scenedesmus	96 hours
		subspicatus	
	Acute EC50 1.4 mg/l	Daphnia	48 hours
	Acute LC50 41.2 mg/l	Fish	96 hours
	Acute LC50 11.17 ppm Fresh water	Fish - Lepomis macrochirus	96 hours
	Chronic NOEC 1.94 ppm	Fish - Oncorhynchus mykiss	49 days
2-methyl-2H-isothiazol-3-one	Acute EC50 0.18 ppm Fresh water	Daphnia - <i>Daphnia magna</i>	48 hours
-	Acute LC50 0.07 ppm Fresh water	Fish - Oncorhynchus mykiss	96 hours
2-Octyl-2H-isothiazol-3-one	Acute EC50 107 ppb Fresh water	Daphnia - <i>Daphnia magna</i>	48 hours
	Acute LC50 47 ppb Fresh water	Fish - Oncorhynchus mykiss	96 hours
	Chronic NOEC 74 ppb Fresh water	Daphnia - <i>Daphnia magna</i>	21 days
	Chronic NOEC 8.5 ppb	Fish - Pimephales promelas	35 days

**Conclusion/Summary** 

: Harmful to aquatic life with long lasting effects.

### 12.2 Persistence and degradability

Product/ingredient name	Test	Result	Dose	Inoculum
7,2-benzisothiazol-3(2H)-one	EU	24 % - 28 days	-	-

**Conclusion/Summary** : This product has not been tested for biodegradation.

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
7,2-benzisothiazol-3(2H)-one Bronopol	-		Inherent Readily

### 12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
2-Butoxyethanol	0.81	-	Low
1,2-benzisothiazol-3(2H)-one	-	3.2	Low
Bronopol	0.18	-	Low
2-Octyl-2H-isothiazol-3-one	2.45	-	Low

Date of issue/Date of revision : 13/06/2022 : 28/09/2023 Date of previous issue Version : 1.07 11/16 Label No :50630

### **SECTION 12: Ecological information**

### 12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

: Not available. **Mobility** 

#### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

### 12.6 Endocrine disrupting properties

Not available.

#### 12.7 Other adverse effects

No known significant effects or critical hazards.

### SECTION 13: Disposal considerations

#### 13.1 Waste treatment methods

#### **Product**

**Methods of disposal** 

: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

: The classification of the product may meet the criteria for a hazardous waste.

**Hazardous waste** 

**European waste** catalogue (EWC) 080112

**Packaging** 

**Methods of disposal** 

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered

when recycling is not feasible.

**Special precautions** 

This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

### **SECTION 14: Transport information**

	ADR/RID	ADN	IMDG	IATA
14.1 UN number or ID number	Not regulated.	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-	-
14.3 Transport hazard class(es)	-	-	-	-
14.4 Packing group	-	-	-	-
14.5 Environmental hazards	No.	No.	No.	No.

Date of issue/Date of revision : 28/09/2023 · 13/06/2022 Version : 1.07 12/16 Date of previous issue Label No : 50630

### SECTION 14: Transport information

user

14.6 Special precautions for : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Maritime transport in bulk according to IMO instruments

: Not relevant/applicable due to nature of the product.

### **SECTION 15: Regulatory information**

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

**Annex XIV** 

None of the components are listed.

Substances of very high concern

None of the components are listed.

### Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Product/ingredient name	%	Designation [Usage]
QUAPRIMER 2900-06	≥90	3

Labelling

Other EU regulations

**Industrial emissions** : Not listed

(integrated pollution prevention and control) -

Air

**Industrial emissions** : Not listed

(integrated pollution prevention and control) -

Water

**Explosive precursors** : Not applicable. Ozone depleting substances (1005/2009/EU)

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

**Persistent Organic Pollutants** 

Not listed.

**Seveso Directive** 

This product is not controlled under the Seveso Directive.

**International regulations** 

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

**Montreal Protocol** 

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

**Rotterdam Convention on Prior Informed Consent (PIC)** 

Not listed.

**UNECE Aarhus Protocol on POPs and Heavy Metals** 

Date of issue/Date of revision : 28/09/2023 · 13/06/2022 Version : 1.07 13/16 Date of previous issue Label No :50630

### **SECTION 15: Regulatory information**

Not listed.

15.2 Chemical safety

: Not applicable.

assessment

### **SECTION 16: Other information**

Indicates information that has changed from previously issued version.

**Abbreviations and** 

: ATE = Acute Toxicity Estimate

acronyms

CLP = Classification, Labelling and Packaging Regulation (EC) No.

1272/2008]

DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard statement

N/A = Not available

PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number

SGG = Segregation Group

vPvB = Very Persistent and Very Bioaccumulative

### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Skin Sens. 1, H317	Calculation method
Aquatic Chronic 3, H412	Calculation method

### Full text of abbreviated H statements

<b>⊮</b> 301	Toxic if swallowed.
H302	Harmful if swallowed.
H311	Toxic in contact with skin.
H312	Harmful in contact with skin.
H314	Causes severe skin burns and eye damage.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H318	Causes serious eye damage.
H319	Causes serious eye irritation.
H330	Fatal if inhaled.
H331	Toxic if inhaled.
H335	May cause respiratory irritation.
H351	Suspected of causing cancer.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
H412	Harmful to aquatic life with long lasting effects.
EUH071	Corrosive to the respiratory tract.

### Full text of classifications [CLP/GHS]

Acute Tox. 2	ACUTE TOXICITY - Category 2
Acute Tox. 3	ACUTE TOXICITY - Category 3
Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatic Acute 1	SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1
Aquatic Chronic 1	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1
Aquatic Chronic 3	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3
Carc. 2	CARCINOGENICITY - Category 2
Eye Dam. 1	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1
Eye Irrit. 2	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2
Skin Corr. 1	SKIN CORROSION/IRRITATION - Category 1
Skin Corr. 1B	SKIN CORROSION/IRRITATION - Category 1B
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2
Skin Sens. 1	SKIN SENSITISATION - Category 1
Skin Sens. 1A	SKIN SENSITISATION - Category 1A
STOT SE 3	SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3

Date of issue/ Date of

: 28/09/2023

revision

Date of issue/Date of revision : 28/09/2023 : 13/06/2022 Version : 1.07 14/16 Date of previous issue Label No : 50630

### **SECTION 16: Other information**

Date of previous issue : 13/06/2022

**Version** : 1.07

#### **Notice to reader**

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a quarantee of the product's properties.

Date of issue/Date of revision : 28/09/2023 Date of previous issue : 13/06/2022 Version : 1.07 15/16 Label No :50630

Version : 1.07 16/16 Date of issue/Date of revision : 28/09/2023 Date of previous issue : 13/06/2022 **Label No** :50630